GlycoSeLect 2022 investment opportunity
GlycoSeLect offers qualifying taxpayers the opportunity to invest in the development of technology for medical research and the biopharmaceutical industry, and avail up to 40% tax relief through the Employment and Investment Incentive Scheme (EIIS).
What is the EIIS?
EII is a tax relief that aims to encourage qualifying individuals to provide equity-based finance to trading companies.
Under the scheme, a taxpayer who puts money into an approved EII investment can reduce a substantial portion of their taxable income for the year in which the investment was made. The maximum investment allowed from 1st January 2020 is:
- €250,000, subject to those shares being held for a minimum period of 4 years or
- €500,000, where those shares are held for a minimum period of 7 years.
Why invest in GlycoSeLect?
GlycoSeLect is a Dublin-based company that develops technology used in the manufacture of pharmaceutical products.
We help reduce the cost and time it takes to bring newest pharmaceuticals, like cancer immunotherapies and vaccines, to the patient.
GlycoSeLect’s technology addresses a biopharmaceutical manufacturing purification market estimated to be valued at $8.6 billion worldwide in 2023.
Our aim is to raise €350,000 in 2022 to develop further applications for our technology and build on our successful interactions with pharmaceutical companies and their equipment suppliers.
In 5 years’ time, with an annualised turnover of €5 million and crucially multiple partnerships, GlycoSeLect will be an attractive company for equity investment or acquisition by a pharmaceutical company or one of their multinational equipment supply companies.
CEO, Robert Dunne, presents EIIS opportunity
- Avail of up to 40% income tax relief
- Qualifying Company
- Proven Technology
- Strong Management Team
- Minimum Investment €5,000
- No entry or exit fees
Contact us now to receive your copy of our investment prospectus and learn more about opportunities at GlycoSeLect: